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Background: Borderline Brenner tumor of the ovary is a rare entity characterized by papillary structures with a
fibro-vascular core, covered by a transitional epithelium, and by the absence of stromal infiltration. It is associated,
by definition, with a benign component of Brenner tumor.
Case: We report a case of a 68-year-old woman, with a right ovarian mass, whose morphology and immuno-profile
were consistent with the diagnosis of a borderline Brenner tumor. Immunohistochemistry carried out on selected
markers may help to formulate the diagnosis, more than the molecular analyses.
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Transitional cell tumors of the ovary, described for the
first time by Brenner in 1907, are rare neoplasms and ac-
count for about 2% of all ovarian tumors.
Transitional cell tumors, in turn, include two distinct
clinic-pathological subtypes: Transitional cell carcinomas
(TCCs) and Brenner Tumors [1].
The World Health Organization (WHO) classifies Brenner
tumors into three categories: benign, borderline and ma-
lignant [2]. Borderline Brenner tumors, usually associated
with a benign Brenner tumor, are characterized by papil-
lary structures with a fibro-vascular core covered by a
transitional epithelium.
Borderline Brenner tumors are negative for p16, Rb
and p53, and show weak immunostaining for Cyclin D1,
moderate for Ras and strong for EGFR. They also express
p63, as in benign subtypes but not in malignant ones, and
present a diffuse staining for CK7, CA125, thrombomodu-
lin and EMA, as in all subtypes of Brenner tumors [3]. Ma-
lignant Brenner tumor is also negative for p16, Rb and p53,
but strongly positive for EGFR, Cyclin D1 and Ras. Over-
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ential diagnosis with TCCs [4].
More recently, molecular analyses have revealed a num-
ber of molecular alterations that allowed to understand
the molecular pathways involved in the pathogenesis and
progression of Brenner Tumors. In particular, the loss of
p16 expression in borderline and malignant Brenner tu-
mors seems to be associated with promoter hyper methy-
lation and a homozygous deletion [5]. Moreover, several
KRAS and PIK3CA somatic mutations have been identi-
fied in about 30% of borderline Brenner tumors [5].
We report the case of a 68-year-old woman with a
right ovarian mass, for which the morphology and im-
munohistochemistry (IHC) analyses were consistent with
the diagnosis of borderline Brenner tumor. Molecular
analyses were also performed to evaluate the methyla-
tion status of p16 and mutational status of KRAS and
PIK3CA. Furthermore, since any activating mutation as-
sociated with EGFR over-expression has been described
in the literature, we also evaluated the mutational status
of the gene and verified EGFR copies number gain or
amplification.
Case presentation
A 68-year-old woman was admitted to gynecological
surgery of our Institute for the presence of a suspectal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Figure 1 Contrast-enhanced CT scan showing a complex and
heterogeneous pelvic mass with inner vegetations and
septations in the anatomic site of the right adnexa (max
diameter 17 cm), not dissociable from uterus and contiguous
bowel (asterisk: pelvic mass; arrows: vegetations and
septations; u: uterus).
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discovered that the patient had been operated 12 years
before for a neoplastic lesion in the left colon, with a
diagnosis of “moderately differentiated adenocarcinoma
infiltrating the muscularis B1 sec. Dukes, pT2 N0 G2”.
No history of endometriosis was reported.
The patient complained of abdominopelvic pain for
two months. Vaginal examination revealed a solid mass
in the right adnexal site attached to pelvis and uterus
(diameter 15 cm Ø approximately) and CA125 levels wereFigure 2 Gross and microscopic description of Brenner tumor: a) Ovar
adeno-fibromatous component (5X); c) H & E representative of cystic formations
cellular component (10X); d) H & E representative of transitional epithelial cells wslightly increased (49.4 IU/ml). Contrast-enhanced CT
scan of abdomen and pelvis revealed a “complex” pelvic
mass (with both cystic and solid components) in the ana-
tomical location of the right adnexa (maximum diameter
17 cm), not dissociable from uterus and contiguous bowel,
with slight peritoneal effusion (Figure 1).
At laparotomy, there was a right adnexal tumor (max-
imum diameter 15 cm) with deep uterine and visceral
adhesions; a total hysterectomy with right salpingo-
oophorectomy and infracolic omentectomy was per-
formed (Figure 2).
Microscopically, the lesion was characterized by a solid
adenofibromatous component with solid nests of transi-
tional epithelial cells with pale cytoplasm, indented nu-
clei and cystic formations lined by mucinous columnar
epithelium and by an exuberant papillary transitional
cellular component with mild nuclear atypia (Figure 2).
The definitive pathological examination showed a Brenner
borderline ovarian tumor with atypia (FIGO stage IA) and
no adjuvant treatment was recommended. The patient
status was NED (no evidence of disease) at 12-month
follow-up visit.
IHC in transitional cells was strongly positive for CK7,
CA125, thrombomodulin and EMA, and negative for
CDX2, CK 20 and p53 (Additional file 1: Figure S1). More-
over, transitional papillary epithelial cells showed a strong
positivity for p63 and EGFR, while p16 appeared positive
in the basal, parabasal and intermediate layer of exophytic
papillary epithelial component (Figure 3).
In order to find p16 promoter hyper-methylation, mo-
lecular analysis was carried out using a commercial kitian mass with solid papillary component; b) H & E representative of a solid
lined by mucinous columnar epithelium and by papillary transitional
ith pale cytoplasm, indented nuclei and mild nuclear atypia (40X).
Figure 3 Borderline Brenner tumor immunoprofile. a) positive immunostaining for CK7 (10X); b) positive immunostaining for EMA (10X);
c) positive immunostaining for thrombomodulin (20X); d) positive immunostaining for EGFR (20X); e) positive immunostaining for p16 (40X);
f) positive immunostaining for p63 (20X).
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the absence of molecular alteration. Mutational analyses
of KRAS and PK3CA were performed by direct se-
quencing, after specific PCR amplification, as previously
reported [3]. The analyses did not reveal the presence of
the mutations described in literature (data not shown).Figure 4 EGFR molecular analyses. a) Absence of mutations detected by
controls of the kit, the blue flat lines indicate our sample); b) Absence of ch
the EGFR gene and green signals represent the centromeric sequence in chro
with 2 red and green signals, ratio = 1; Magnification, ×60)).Finally, mutational analysis of EGFR was performed by a
commercial kit (EGFR Mutation Analysis Kit, EntroGen,
Tarzana, CA, USA), containing a distinct primer/probe
mix in order to detect, by Real Time PCR system, all EGFR
point mutations described in literature (Exons 18, 19, 20,
21). No activating mutations were present in our sample.RT-PCR method (the yellow increased curves indicate the internal
romosomal aberrations detected by FISH method (red signals represent
mosome 7. The above picture shows a balanced disomy (each nucleus
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7 SpectrumGreen Probe, Vysis Abbott) did not reveal gene
amplification or gene copies number gain (Figure 4).
However, morphology and immuno-profile of the sample
were consistent with the diagnosis of a borderline Brenner
tumor of the ovary.
Discussion
Brenner tumors of the ovary are rare cancers. Up to
date, about 30 cases of Brenner borderline tumors have
been described, all characterized by the absence of stro-
mal infiltration and, by definition, associated with a be-
nign component [6]. These lesions seem to originate
from transitional metaplasia of the tubal epithelial cells
[7]. As for low-grade ovarian serous carcinomas, the ac-
quisition of a series of molecular alterations lead to its
evolution from a benign lesion [8].
Our case of borderline Brenner tumor is morphologic-
ally characterized by papillary projections and solid nests
of transitional cells surrounded by dense fibrous tissue.
Transitional cells showed only mild, focal nuclear
atypia and low mitotic index; extensive sampling ruled
out infiltration. Therefore, our diagnosis was “Brenner
Borderline tumor with atypia” [9].
We performed an immunohistochemical study to dem-
onstrate the origin of the tumor from the ovary and then
to exclude that it was a metastasization from the bowel.
The immunohistochemical panel showed strong posi-
tivity for p63 and EGFR in the epithelial component
of the tumor, while p16 was positive in the basal, paraba-
sal and intermediate layer of the papillary epithelial
component.
We also found, in transitional cells, a strong cell posi-
tivity for CK7, CA125, thrombomodulin and EMA, con-
firming the ovarian origin, and a negativity for CDX2
and CK 20. These latter findings excluded, immunophe-
notypically, the presence of metastasis from the primary
tumor of the colon, dating back 12 years earlier.
In the light of recent findings on the role of some mo-
lecular markers in the pathogenesis and progression of
this tumor [5], we have also carried out molecular ana-
lyses to verify the methylation of p16 promoter and mu-
tational status of KRAS, PIK3CA and EGFR. For the
latter we have also looked for potential aberrations at
gene/chromosome level. None of the performed molecu-
lar analyses showed positive results and, above all, they
did not provide any important support to the histomor-
phological diagnosis.
Conclusions
Our case can be placed among the low-grade lesions, based
on morphology and immunophenotype. As described for
papillary serous ovarian tumors of low-grade, the presence
of specific markers has been of fundamental support forthe differential diagnosis with benign (low expression of
EGFR and p16) and malignant (negative for p16) Brenner
tumors, and with TCCs (negative for EGFR).
However, the molecular alterations described in litera-
ture, currently do not seem to be so specific as to suggest
the possibility of developing targeted biological therapies
for these lesions. Therefore, it would be necessary to bet-
ter characterize these lesions, from a molecular point of
view. Although they do not show a tendency to evolve into
more aggressive malignancies, very little is known about
cell biology that determines its pathogenesis.
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